Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase-Reference-Cited by-同舟云学术

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase

Published:2020-04-27 Issue:15 Volume:63 Page:8025-8042
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Schulze Volker K.¹^ORCID,Klar Ulrich¹,Kosemund Dirk¹,Wengner Antje M.¹,Siemeister Gerhard¹,Stöckigt Detlef¹,Neuhaus Roland¹,Lienau Philip¹,Bader Benjamin¹,Prechtl Stefan¹,Holton Simon J.¹,Briem Hans¹,Marquardt Tobias²,Schirok Hartmut²,Jautelat Rolf²,Bohlmann Rolf¹,Nguyen Duy¹^ORCID,Fernández-Montalván Amaury E.¹^ORCID,Bömer Ulf¹,Eberspaecher Uwe¹,Brüning Michael¹,Döhr Olaf¹,Raschke Marian¹,Kreft Bertolt¹,Mumberg Dominik¹,Ziegelbauer Karl¹,Brands Michael¹,von Nussbaum Franz¹,Koppitz Marcus¹

Affiliation:

1. Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany

2. Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b02035

Reference25 articles.

1. Hallmarks of Cancer: The Next Generation

2. Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosis